Signos pairs glucose with an AI to tackle weight management while bringing visibility into metabolic function and guidance to better health.
Signos has raised $20.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2026.
Signos's investors include Samsung NEXT, Dexcom, 1984 Ventures, Google Ventures, Tau Ventures.
Signos is headquartered in Burlingame, United States.
Signos pairs glucose with an AI to tackle weight management while bringing visibility into metabolic function and guidance to better health.
Signos is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Signos — Funding & Investors." VCBacked, May 27, 2026, https://www.vcbacked.co/company/signos. Accessed July 19, 2026.
VCBacked. (2026). Signos — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/signos
{{cite web |title=Signos — Funding & Investors |url=https://www.vcbacked.co/company/signos |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated